Canaccord initiated coverage of Adma Biologics (ADMA) with a Buy rating and $21 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- Adma Biologics price target lowered to $24 from $30 at Mizuho
- Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
- Adma Biologics call volume above normal and directionally bullish
- ADMA Biologics Issues Rebuttal to Short-Seller Allegations
- Adma Biologics responds to short seller report by Culper Research